Gilead Sciences: all 734 studies

Page 6 of 8. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

• Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With IdelalisibTerminatedNCT03701438
• Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and IrelandCompletedNCT03582098
• Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir AlafenamideCompletedNCT03580668
• Safety Profile of Idelalisib in Patients With Refractory Follicular LymphomaCompletedNCT03568929
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsCompletedNCT03369002Phase 1
• Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
• Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)Active, not recruitingNCT03301506Phase 3
• Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingNCT03153462
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced CancersTerminatedNCT03139370Phase 1
• Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in KoreaCompletedNCT02951364
• Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionActive, not recruitingNCT02932150Phase 2
• Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in KoreaCompletedNCT02907996
• Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1Active, not recruitingNCT02881320Phase 2/3
• Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult SubjectsCompletedNCT02876796Phase 1
• Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical PracticeCompletedNCT02783976
• CAMELLIA: Anti-CD47 Antibody Therapy in Haematological MalignanciesCompletedNCT02678338Phase 1
• Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT02625480Phase 1/2
• Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in IndiaCompletedNCT02592057
• Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT02591277
• Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02562742
• Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02537379
• A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsTerminatedNCT02510300
• Study to Evaluate the Effects of MBX-8025 in Patients With HoFHCompletedNCT02472535Phase 2
• Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal FunctionCompletedNCT02441829Phase 1
• GS-6615 in Adults With Chronic Stable Angina and Coronary Artery DiseaseWithdrawnNCT02377336Phase 2
• Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy AdultsCompletedNCT02365532Phase 1
• Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B InfectionTerminatedNCT02258581
• Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
• Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutCompletedNCT02252835Phase 2
• Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)CompletedNCT02247934
• Phase 1 Trial of Hu5F9-G4, a CD47-targeting AntibodyCompletedNCT02216409Phase 1
• Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy AdultsCompletedNCT02209987Phase 1
• Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid ArthritisCompletedNCT02176876Phase 1
• Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerWithdrawnNCT02161679Phase 2
• Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic LeukemiaApproved for marketingNCT02136511
• Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout PatientsCompletedNCT02063997Phase 2
• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingNCT02016924Phase 2/3
• Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic CancerTerminatedNCT01956812Phase 3
• A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal CancerWithdrawnNCT01915472Phase 2
• Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)CompletedNCT01906255
• A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)CompletedNCT01902472
• A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With SclerodermaCompletedNCT01881529
• A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USACompletedNCT01865799
• A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP IndicationCompletedNCT01865786
• A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected SubjectsCompletedNCT01850212
• Study of the Effect of GS-6615 in Subjects With LQT-3CompletedNCT01849003Phase 1
• A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy SubjectsCompletedNCT01847391Phase 1
• Phase Ib Study of SC Milatuzumab in SLECompletedNCT01845740Phase 1
• A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.CompletedNCT01843127Phase 1
• A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 PharmacokineticsCompletedNCT01841489Phase 1
• Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CFCompletedNCT01840735Phase 1
• A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentCompletedNCT01817985Phase 1
• A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806CompletedNCT01801293Phase 1
• Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)WithdrawnNCT01797419Phase 1
• A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy SubjectsTerminatedNCT01793649Phase 1
• Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis CApproved for marketingNCT01779518
• A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy AdultsCompletedNCT01779505Phase 1
• Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in IndiaCompletedNCT01772121
• Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)CompletedNCT01756482Phase 2
• Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of AgeCompletedNCT01754428
• Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
• A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid MalignanciesCompletedNCT01705847Phase 1
• A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of RanolazineTerminatedNCT01675973Phase 1
• A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis BCompletedNCT01671787Phase 1
• Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
• A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic LeukemiaWithdrawnNCT01659047Phase 2
• Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal CancerTerminatedNCT01605318Phase 1/2
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis CCompletedNCT01591668Phase 1
• A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus InfectionCompletedNCT01590654Phase 1
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis BCompletedNCT01590641Phase 1
• Registry Study for Patients With Chronic HBV Receiving Nucleotide TherapyCompletedNCT01590615
• Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLTerminatedNCT01585688Phase 1/2
• Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With RanolazineCompletedNCT01546597Phase 1
• Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mgCompletedNCT01546558Phase 1
• A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.WithdrawnNCT01510561Phase 1
• Open-Label Hepatic Impairment StudyCompletedNCT01497327Phase 1
• A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic AdenocarcinomaCompletedNCT01472198Phase 2
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseCompletedNCT01457768
• Gilead Sustained Virologic Response (SVR) RegistryCompletedNCT01457755
• Pilot Study of Simtuzumab in the Treatment of Liver FibrosisCompletedNCT01452308Phase 2
• GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01435226Phase 2
• Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C InfectionCompletedNCT01435044Phase 2
• GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01434498Phase 2
• Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01431898Phase 1
• Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout PatientsCompletedNCT01416402Phase 2
• GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeTerminatedNCT01384383Phase 2
• Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis PatientsCompletedNCT01375036
• Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
• A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01362231Phase 1
• GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusCompletedNCT01356160Phase 2
• GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01353248Phase 2
• Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With GoutCompletedNCT01336686Phase 2
• Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in TaiwanCompletedNCT01334567Phase 2
• A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)WithdrawnNCT01334203Phase 4
• First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid TumorsCompletedNCT01323933Phase 1
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01316237Phase 1
• Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal CancerWithdrawnNCT01273402Phase 1
• A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01271790Phase 2
• Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal CancerCompletedNCT01270698Phase 1

← Gilead Sciences overview and focus areas